NasdaqGS - Delayed Quote USD

Karyopharm Therapeutics Inc. (KPTI)

1.0900 0.0000 (0.00%)
At close: April 24 at 4:00 PM EDT
1.0900 0.00 (0.00%)
After hours: April 24 at 7:39 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Richard A. Paulson M.B.A. President, CEO & Director 1.43M -- 1967
Mr. Cameron Peters Vice President of Finance, Assistant Treasurer & Principal Accounting Officer -- -- 1960
Ms. Elhan Webb C.F.A. Senior Vice President of Investor Relations -- -- --
Dr. Amama Sadiq M.D., M.P.H. Senior Vice President of Global Medical & Scientific Affairs -- -- --

Karyopharm Therapeutics Inc.

85 Wells Avenue
Suite 210
Newton, MA 02459-3298
United States
617 658 0600 https://www.karyopharm.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
325

Description

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Corporate Governance

Karyopharm Therapeutics Inc.’s ISS Governance QualityScore as of April 1, 2024 is 8. The pillar scores are Audit: 8; Board: 8; Shareholder Rights: 8; Compensation: 7.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 02, 2024 - May 06, 2024
Karyopharm Therapeutics Inc. Earnings Call

Related Tickers

TGTX TG Therapeutics, Inc.
13.98
-1.89%
 
MCRB Seres Therapeutics, Inc.
0.7295
-4.01%
 
HRTX Heron Therapeutics, Inc.
2.6500
-5.36%
 
MRNS Marinus Pharmaceuticals, Inc.
1.4400
0.00%
 
ADAP Adaptimmune Therapeutics plc
1.0800
-5.26%
 
CHRS Coherus BioSciences, Inc.
2.0200
-7.34%
 
BLUE bluebird bio, Inc.
0.9229
-4.91%
 
ADCT ADC Therapeutics SA
4.7800
-3.82%
 
TSVT 2seventy bio, Inc.
4.2700
-7.78%
 
OCUL Ocular Therapeutix, Inc.
4.6450
-7.10%